• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Soligenix, Inc. - Common Stock (NQ:SNGX)

    1.790 -0.020 (-1.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,659,220
    Open 1.850
    Bid (Size) 1.780 (1)
    Ask (Size) 1.810 (5)
    Prev. Close 1.810
    Today's Range 1.780 - 1.970
    52wk Range 1.090 - 6.230
    Shares Outstanding 3,504,950
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
    Via Investor Brand Network
    Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally
    Via Stocktwits

    Performance

    YTD
    -39.1%
    -39.1%
    1 Month
    -33.2%
    -33.2%
    3 Month
    +40.9%
    +40.9%
    6 Month
    -5.3%
    -5.3%
    1 Year
    -55.4%
    -55.4%

    More News

    Read More
    BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
    Via Investor Brand Network
    Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm
    Via Investor Brand Network
    BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
    Via Investor Brand Network
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
    Via Investor Brand Network
    Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
    Via Investor Brand Network
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Which stocks are experiencing notable movement on Friday?
    Via Chartmill
    Friday's session: gap up and gap down stocks
    Via Chartmill
    What's going on in today's pre-market session
    Via Chartmill
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
    Via Investor Brand Network
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Keep an eye on the top gainers and losers in Tuesday's session.
    Via Chartmill
    BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
    Via Investor Brand Network
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
    Via Investor Brand Network
    UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy
    Via Investor Brand Network
    Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
    Via Investor Brand Network
    Senior NIH Officials Allege Retaliation as Motive for Their Ouster
    Via Investor Brand Network
    Topics Whistleblower
    BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
    Via Investor Brand Network
    Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
    Via Investor Brand Network
    InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
    Via Investor Brand Network
    Study Explains Why Blood Clotting is Common in IBD Patients
    Via Investor Brand Network

    Frequently Asked Questions

    Is Soligenix, Inc. - Common Stock publicly traded?
    Yes, Soligenix, Inc. - Common Stock is publicly traded.
    What exchange does Soligenix, Inc. - Common Stock trade on?
    Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Soligenix, Inc. - Common Stock?
    The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
    What is the current price of Soligenix, Inc. - Common Stock?
    The current price of Soligenix, Inc. - Common Stock is 1.790
    When was Soligenix, Inc. - Common Stock last traded?
    The last trade of Soligenix, Inc. - Common Stock was at 10/09/25 04:00 PM ET
    What is the market capitalization of Soligenix, Inc. - Common Stock?
    The market capitalization of Soligenix, Inc. - Common Stock is 6.27M
    How many shares of Soligenix, Inc. - Common Stock are outstanding?
    Soligenix, Inc. - Common Stock has 6M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.